714TiP A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors

• Published in: Annals of oncology Vol. 34; p. S494
• Main Authors: Luen, S.J., Ahern, E.S., Berger, C., Desai, J., Frentzas, S., Gan, H., Gualandi, M., Markman, B., Millward, M., Rafiei, A., Tran, B., Renner, C.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.10.2023